ALT logo

ALT
Altimmune Inc

40,972
Mkt Cap
$593.15M
Volume
2.6M
52W High
$7.73
52W Low
$2.56
PE Ratio
-3.25
ALT Fundamentals
Price
$3.05
Prev Close
$3.07
Open
$3.07
50D MA
$3.11
Beta
1.60
Avg. Volume
4.83M
EPS (Annual)
-$0.9999
P/B
1.40
Rev/Employee
$719.30
$80.25
Loading...
Loading...
News
all
press releases
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.
Stocktwits
News Placeholder
More News
News Placeholder
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data fueling investor focus.
Zacks
News Placeholder
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.
Zacks
News Placeholder
WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues
Waters crushes Q1 2026 estimates as revenues surge 91.5%; newly acquired BD units top targets early, and 2026 guidance moves higher.
Zacks
News Placeholder
Altimmune (ALT) Projected to Post Earnings on Tuesday
Altimmune (NASDAQ:ALT) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-altimmune-inc-stock...
MarketBeat
News Placeholder
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead
VKTX rose about 1.4% over the past month, beating Altimmune, Amgen, and Structure Therapeutics; however, Novo Nordisk led the pack with a 17.3% gain.
Stocktwits
News Placeholder
Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from Analysts
Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and s...
MarketBeat
News Placeholder
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff?
The decline was driven by concerns about factors ranging from leadership gaps and financial pressure to an unclear strategic direction.
Stocktwits
News Placeholder
Altimmune Catalysts: 2026 Data Readouts and Financing Risks
ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.
Zacks
News Placeholder
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.
Zacks
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available